Icelandirect, a U.S.-based contract manufacturer and portfolio company of New Heritage Capital, announced it has acquired SOMA LABS, a New Jersey-based supplement manufacturer specializing in solid dosage form production.
The transaction closed in February 2026 and represents a strategic expansion of Icelandirect’s manufacturing capabilities across both human nutrition and pet supplement markets. The deal enables the company to broaden its offering beyond its established strengths in lipid and softgel sourcing, formulation, manufacturing, and packaging.
With the acquisition, Icelandirect is adding new dosage form capabilities, including powders, capsules, tablets, and chewables. This expansion allows the company to provide a more comprehensive, end-to-end solution for brands, covering everything from ingredient sourcing and formulation to finished, shelf-ready products.
SOMA LABS will operate as an integrated division within Icelandirect, with its New Jersey facility remaining fully operational. The integration of leadership and technical teams is expected to ensure continuity across quality systems, supply chain operations, and customer service, while also giving existing SOMA LABS customers access to Icelandirect’s broader infrastructure and capabilities.
The combined platform positions Icelandirect to scale production, support a wider range of product formats, and meet growing demand across both human and pet supplement categories.
KEY QUOTE:
“For years, we have been known as a leader in lipid and softgel supplement sourcing, formulation, manufacturing and packaging. The acquisition of SOMA LABS will allow us to add powder, tablet, capsule, and chewable capabilities, thus delivering a turnkey product offering to our clients. These new offerings allow us to take a brand from ingredient and formula all the way through to finished, shelf-ready product, in more formats, at greater scale, and with the quality standards our customers have come to expect from Icelandirect.”
Brandon Miller, CEO of Icelandirect
